Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJBHO0)

Drug Name

PC-DAC:Insulin Drug Info

Synonyms

Capsulin; Intesulin; Macrulin; Nodlin; SuliXen; AERx Diabetes Management System; AERx iDMS; Capsulin IR; Capsulin OAD; Capsulin insulin replacement; Insulin tregopil; Ultrafast Insulin program; HIM2; AERx (insulin); AT-1391; AT-2391; Analog-PH20; CADDYS (insulin); CJC-1530; CJC-1531; CJC-1575; CJC-1576; Capsulin oral anti-diabetic; DTY-001; GW-843362; GW-843362M; Hexyl insulin monoconjugate, Nobex; IN-105; Inhaled insulin, Andaris; Insulin-PH20; Intesulin-1; Intesulin-IVE; NB-058; NIN-058; NN-1998; ORMD-0801; Oral insulin, Emisphere; Oral insulin, Nobex; PC-Insulin; Inhaled insulin, QDose/BMS; Inhaled insulin, Quadrant/MicroDose; Insulin (inhaled), Aradigm; Insulin (inhaled), QDose; Insulin (inhaled),Translational Research; Insulin (oral), Biocon; Insulin (oral), Coremed; Insulin (oral), Protein Delivery Inc; Insulin (pulmonary), Translational Research; MicroPor (insulin), Altea

Indication

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Phase 3	[1]
Type-2 diabetes	5A11	Phase 2	[2]

Cross-matching ID

TTD Drug ID: DMJBHO0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Insulin (INS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inulin	DM1Y2JH	Measure kidney function	MG02	Approved	[4]
Insulin Zinc Susp Recombinant Human	DM6MO9X	Diabetic complication	5A2Y	Approved	[4]
Insulin-glargine	DMR4HIW	Diabetic complication	5A2Y	Approved	[4]
Insulin Susp Isophane Recombinant Human	DMW8KI7	Diabetic complication	5A2Y	Approved	[4]
Insulin determir	DM79NZ5	Diabetic complication	5A2Y	Approved	[5]
Insulin Susp Protamine Zinc Beef/Pork	DM0NATE	Diabetic complication	5A2Y	Approved	[4]
Insulin-aspart	DMX7V28	Diabetic complication	5A2Y	Approved	[4]
Insulin degludec	DMPL395	Type-1/2 diabetes	5A10-5A11	Approved	[6]
Insulin-detemir	DMOA4VW	Type-1/2 diabetes	5A10-5A11	Approved	[4]
LY2963016	DMEZ0H5	Type-1/2 diabetes	5A10-5A11	Phase 3	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin (INS)	TTZOPHG	INS_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00411892) Effect of Inhaled Insulin (AERx iDMS) on Blood Glucose Control in Type 2 Diabetes. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin. J Diabetes Sci Technol. 2010 May; 4(3): 532-539.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
6	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
7	Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33.